-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[May 24, 2021/Medical Information List] Director of Nanjing Pharmaceuticals resigns; another pharmaceutical company stops on the Sci-tech Innovation Board; TongYongkang Pharmaceutical has completed nearly 400 million yuan in B+ round of financing.
[May 24, 2021/Medical Information List] Daily news about fresh medicines and medical news, speed reading and follow you together!
Part1 Policy Brief
Part1 policy briefing Part1 policy briefingThe latest notice of the State Food and Drug Administration on the active recall of medical devices involves artificial blood vessels and other devices
The latest notice of the State Food and Drug Administration on the active recall of medical devices involves artificial blood vessels and other devicesOn May 21, the State Food and Drug Administration issued the latest notice on the voluntary recall of medical devices, including Zimmer GmbH's voluntary recall of Metallic Intramedullary Nail, and Gore & Associates, Inc.
Buy new news with volume! Beijing implementation time has been determined
Buy new news with volume! Beijing implementation time has been determinedOn May 21, the Beijing Municipal Medical Insurance Bureau issued the "Notice on the implementation of the first, second, and fourth batches of nationally organized drug centralized procurement and Beijing-Tianjin-Hebei drug joint procurement of drugs related to the results of the selection.
National Food and Drug Administration: Cancellation of 283 drug approvals and 139 medical device registrations
National Food and Drug Administration: Cancellation of 283 drug approvals and 139 medical device registrationsOn May 24, the State Food and Drug Administration issued an announcement stating that in accordance with relevant laws, it has decided to cancel 283 drug registration certificates including megestrol acetate dispersible tablets, and 139 medical device products have been approved for registration.
Part2 Observation
Part2 Sankei Observation Part2 Sankei ObservationDirector of Nanjing Pharmaceutical resigns
Director of Nanjing Pharmaceutical resignsOn May 24, Nanjing Pharmaceutical issued an announcement stating that the board of directors received a written resignation report from the company’s director, Mr.
Li Shuhong resigned as director of Hao Ober and many other positions
Li Shuhong resigned as director of Hao Ober and many other positionsOn May 24, Jiangsu Hoobo Biomedical issued an announcement stating that the board of directors had recently received a written resignation report from the director, secretary of the board and chief financial officer, Ms.
Another pharmaceutical company stopped the science and technology innovation board
Another pharmaceutical company stopped the science and technology innovation boardRecently, the Shanghai Stock Exchange issued an announcement stating that the decision to terminate the review of Ruibo Biological’s initial public offering and listing on the Science and Technology Innovation Board.
GlaxoSmithKline sells Innoviva for $392 million
GlaxoSmithKline sells Innoviva for $392 millionA few days ago, GlaxoSmithKline announced in a statement that it has decided to sell all 32 million Innoviva common stocks to Innoviva at a price of $12.
Fangsheng Pharmaceutical's subsidiary Baijun Medical and DaVita reached a strategic cooperation
Fangsheng Pharmaceutical's subsidiary Baijun Medical and DaVita reached a strategic cooperationOn the afternoon of the 24th, Baijun Medical, a subsidiary of Fangsheng Pharmaceuticals, signed a strategic cooperation agreement in Changsha with Davit Corporation of the United States.
TongYongkang Pharmaceutical completed nearly 400 million yuan in B+ round of financing
TongYongkang Pharmaceutical completed nearly 400 million yuan in B+ round of financingRecently, TongYongkang Pharmaceutical announced the completion of nearly 400 million yuan in B+ round of financing.
Jianshi Medical Receives Hundreds of Million Dollars in Series B Financing
Jianshi Medical Receives Hundreds of Million Dollars in Series B FinancingAccording to reports, the emerging medical technology company Jianshi Medical Technology Group recently received hundreds of millions of dollars in Series B financing.
Part3 Medicine News
Part3 Medicine News Part3 Medicine NewsRenfu Class 1 New Drug Propofol Disodium for Injection Approved for Marketing
Renfu Class 1 New Drug Propofol Disodium for Injection Approved for MarketingOn May 24, the official website of NMPA showed that Renfu’s Class 1 new drug, propofol disodium for injection, was approved for marketing, and the indication was general anesthesia induction.
Xintian Pharmaceutical's avanafil tablets obtained drug registration approval
Xintian Pharmaceutical's avanafil tablets obtained drug registration approvalRecently, Xintian Pharmaceutical issued an announcement stating that its wholly-owned subsidiary Huilun Jiangsu Pharmaceutical received the approval of the National Medical Products Administration to issue a "drug registration certificate" for avanafil tablets.
Tosunshine Aripiprazole Orally Disintegrating Tablets Approved
Tosunshine Aripiprazole Orally Disintegrating Tablets ApprovedOn May 24, Dongyang Sunshine issued an announcement stating that the subsidiary had recently received the "Drug Registration Certificate" approved and issued by the Food and Drug Administration.
Ganli Pharmaceutical Protamine Recombinant Human Insulin (premixed 30R) was officially approved
Ganli Pharmaceutical Protamine Recombinant Human Insulin (premixed 30R) was officially approvedOn May 24, NMPA issued a drug approval document.
Nanjing Chia Tai Tianqing "Tolvaptan" was approved to be listed as the second domestic manufacturer
Nanjing Chia Tai Tianqing "Tolvaptan" was approved to be listed as the second domestic manufacturerOn May 24, NMPA issued an approval document, and Nanjing Chia Tai Tianqing's generic drug "Tolvaptan" was approved for listing, making it the second domestic manufacturer to be approved.
Yangtze River and CSPC ``Lignagliptin'' were approved for listing
Yangtze River and CSPC ``Lignagliptin'' were approved for listing
On May 24, NMPA issued an approval document, and both Yangzijiang Pharmaceutical and CSPC Ouyi's four generic drugs "Litagliptin Tablets" were approved for listing.
This medicine is used as a single agent/in combination with metformin/in combination with metformin and sulfonylureas to treat type 2 diabetes.
(Insight database)
Haisco: IND application for new indications for HSK21542 injection has been accepted
Haisco: IND application for new indications for HSK21542 injection has been accepted
On May 24, Haisco announced that the company has obtained the "Notice of Acceptance" for the IND application for the new indication of the innovative drug HSK21542 injection.
HSK21542 injection is a brand-new analgesic drug with independent intellectual property rights developed by Haisco.
It is intended to be used for the treatment of acute and chronic pain, itching and other indications.
(Hisco announcement)
Novartis' innovative triple therapy is approved in China
Novartis' innovative triple therapy is approved in China
On May 24, China’s National Food and Drug Administration announced that Novartis’ indacaterol/glycopyrrolate/mometasone furoate inhalation powder has been officially approved in China.
It is reported that the drug is mainly used to treat patients with uncontrolled asthma.
(Medicine Guanlan)
Sialon Pharmaceuticals: The company's omeprazole sodium for injection passed the consistency evaluation of generic drugs
Sialon Pharmaceuticals: The company's omeprazole sodium for injection passed the consistency evaluation of generic drugs
On May 24, Sialon Pharmaceutical announced that the company's omeprazole sodium for injection passed the consistency evaluation of generic drugs.
The main indication of Omeprazole Sodium for Injection is to treat acute upper gastrointestinal bleeding caused by duodenal ulcer, gastric ulcer, acute gastric mucosal disease, compound ulcer and so on.
(Sialon Pharmaceutical Announcement)
BeiGene's first-in-class HPK1 inhibitor is applied for clinical application in China
BeiGene's first-in-class HPK1 inhibitor is applied for clinical application in China
On May 24, the CDE official website showed that BeiGene's first-in-class HPK1 inhibitor BGB-15025 capsule clinical application was officially accepted by NMPA for the treatment of solid tumors.
(Medical Rubik's Cube Info)
